Silgan plans to acquire Trivium, which it will seperate into two standalone packaging companies. Prescription pharma dispensing products grew by double digits in North America.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Silgan NYSE: SLGN reported third-quarter 2026 adjusted earnings per share of $1.31, up 7% from the prior-year period and at the top of its projected range, as higher operating profit and lower interest expense more than offset a higher adjusted tax rate.
Although the revenue and EPS for Silgan (SLGN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Silgan Holdings (SLGN) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.22 per share a year ago.